The comparative effects of pioglitazone and rosiglitazone on lipoprotein sub-fractions in patients with type 2 diabetes and dyslipidemia

被引：0
|
作者：
Deeg, MA
Goldberg, RB
Buse, JB
Kendall, DM
Zagar, AJ
Pinaire, JA
Tan, MH
Khan, MA
Perez, AT
Jacober, SJ
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A234 / A235
页数：2
相关论文
共 50 条
  • [1] Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    Deeg, Mark A.
    Buse, John B.
    Goldberg, Ronald B.
    Kendall, David M.
    Zagar, Anthony J.
    Jacober, Scott J.
    Khan, Mehmood A.
    Perez, Alfonzo T.
    Tan, Meng H.
    DIABETES CARE, 2007, 30 (10) : 2458 - 2464
  • [2] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    CIRCULATION, 2005, 111 (13) : 1727 - 1728
  • [3] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    DIABETES CARE, 2005, 28 (07) : 1547 - 1554
  • [4] Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids
    Brackenridge, A. L.
    Jackson, N.
    Jefferson, W.
    Stolinski, M.
    Shojaee-Moradie, F.
    Hovorka, R.
    Umpleby, A. M.
    Russell-Jones, D.
    DIABETIC MEDICINE, 2009, 26 (05) : 532 - 539
  • [5] A comparison of effects of pioglitazone and rosiglitazone on serum lipoproteins and their subfractions in patients with type 2 diabetes and dyslipidemia
    Tan, MH
    Kendall, DM
    Deeg, MA
    Buse, JB
    Goldberg, R
    Zagar, AJ
    Khan, MA
    Perez, AT
    Jacober, SJ
    DIABETOLOGIA, 2005, 48 : A393 - A394
  • [6] A comparison of nontraditional atherogenic markers with pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Law, R
    Khan, M
    Perez, A
    Jacober, S
    Goldberg, R
    Kendall, D
    Deeg, M
    Tan, M
    Demissie, S
    DIABETOLOGIA, 2005, 48 : A286 - A286
  • [7] Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
    Berneis, Kaspar
    Rizzo, Manfredi
    Stettler, Christoph
    Chappuis, Bernard
    Braun, Monica
    Diem, Peter
    Christ, Emanuel R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (03) : 343 - 349
  • [8] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia - Response to Bell and Brunzell
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    DIABETES CARE, 2005, 28 (12) : 2985 - 2986
  • [9] Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries, Corinne S.
    Russell-Jones, David L.
    BRITISH MEDICAL JOURNAL, 2009, 339
  • [10] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
12345